Marinus Pharmaceuticals, Inc. (0JYL.L)

1,3950 -0,0428 (-2,98%) Alla chiusura: 06:20PM BST

Marinus Pharmaceuticals, Inc.

5 Radnor Corporate Center
Suite 500 100 Matsonford Road
Radnor, PA 19087
United States
484 801 4670
https://marinuspharma.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 165

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Scott N. Braunstein M.D.	CEO, President & Chairman	1,01M	N/D	1963
Mr. Steven E. Pfanstiel C.M.A., M.B.A.	COO, CFO & Treasurer	670,25k	N/D	1973
Dr. Joseph Hulihan M.D.	Chief Medical Officer	665,47k	N/D	1957
Dr. Alex Aimetti Ph.D.	Chief Scientific Officer	N/D	N/D	N/D
Ms. Sonya Weigle	Senior VP of Investor Relations, Human Resources & Corporate Affairs	N/D	N/D	N/D
Ms. Martha E. Manning Esq., J. D.	Senior VP, General Counsel & Secretary	N/D	N/D	1955
Molly Cameron	Director of Corporate Communications & Investor Relations	N/D	N/D	N/D
Dr. Kimberly A. McCormick Pharm.D.	Chief Regulatory & Quality Assurance Officer	N/D	N/D	N/D
Mr. Thomas J. Lyons	Chief Business Officer	N/D	N/D	N/D
Ms. Christina Shafer	Chief Commercial Officer	N/D	N/D	1977

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Governance aziendale

L'ISS Governance QualityScore di Marinus Pharmaceuticals, Inc. al 1 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 8; diritti degli azionisti: 6; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.